These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 17602080)

  • 21. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
    Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer].
    Han XP; Zhang X
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(30):2115-8. PubMed ID: 21029626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
    Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
    Wachters FM; Wong LS; Timens W; Kampinga HH; Groen HJ
    Lung Cancer; 2005 Nov; 50(2):211-9. PubMed ID: 16169122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
    Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
    Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S; Takabe K; Suzuki K
    Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
    Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
    Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.